NCT00721214View on ClinicalTrials.gov

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

5-azacytidine

The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.

Trial Locations (1)

23298

Massey Cancer Center / Virginia Commonwealth University, Richmond

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Virginia Commonwealth University

OTHER